Immune Therapy for the Treatment of Osteosarcoma
The immune system plays an important role in identifying and killing cancer cells in the body.
The Mason lab is currently evaluating a vaccine, called ADXS31-164, that aims to stimulate the body’s immune system to recognize and kill bone cancer cells.
The vaccine is made from the bacteria Listeria monocytogenes, which has been genetically modified to express a tumor protein (HER-2/neu) that is found in many cancer cells, including canine osteosarcoma.
The bacteria is highly attenuated, which means it has been weakened so as not to cause disease when administered to the patient.
The vaccine is given by intravenous injection and aims to stimulate an immune response against cells that express the tumor protein (HER2/neu).
In this way, it is hoped that the immune system can be trained to recognize both primary and metastatic cancer cells and eliminate them, helping to delay the onset of metastatic disease and in cases where dogs are treated without amputation, prevent primary tumor progression.